These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15955107)

  • 1. Clusterin regulates drug-resistance in melanoma cells.
    Hoeller C; Pratscher B; Thallinger C; Winter D; Fink D; Kovacic B; Sexl V; Wacheck V; Gleave ME; Pehamberger H; Jansen B
    J Invest Dermatol; 2005 Jun; 124(6):1300-7. PubMed ID: 15955107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
    Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
    J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
    Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
    Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
    Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
    Yamanaka K; Gleave M; Muramaki M; Hara I; Miyake H
    Oncol Rep; 2005 May; 13(5):885-90. PubMed ID: 15809754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H; Hara I; Kamidono S; Gleave ME
    Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
    Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
    Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
    Olie RA; Hafner C; Küttel R; Sigrist B; Willers J; Dummer R; Hall J; Stahel RA; Zangemeister-Wittke U
    J Invest Dermatol; 2002 Mar; 118(3):505-12. PubMed ID: 11874491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H; Yamanaka K; Muramaki M; Hara I; Gleave ME
    Neoplasia; 2005 Feb; 7(2):171-9. PubMed ID: 15802022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H; Chi KN; Gleave ME
    Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo.
    Hara I; Miyake H; Gleave ME; Kamidono S
    Jpn J Cancer Res; 2001 Nov; 92(11):1220-4. PubMed ID: 11714447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of bcl-2 antisense oligonucleotides on multidrug resistance of cultured uveal melanoma cells].
    Guo LJ; Wu ZY; Zhang S; Zheng JL; Zheng HL
    Zhonghua Yan Ke Za Zhi; 2003 Feb; 39(2):73-6. PubMed ID: 12783683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
    Hu Y; Cherton-Horvat G; Dragowska V; Baird S; Korneluk RG; Durkin JP; Mayer LD; LaCasse EC
    Clin Cancer Res; 2003 Jul; 9(7):2826-36. PubMed ID: 12855663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
    Springate CM; Jackson JK; Gleave ME; Burt HM
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clusterin inhibits apoptosis by interacting with activated Bax.
    Zhang H; Kim JK; Edwards CA; Xu Z; Taichman R; Wang CY
    Nat Cell Biol; 2005 Sep; 7(9):909-15. PubMed ID: 16113678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
    Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
    J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.
    Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E
    J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.